Dabigatran Following Transient Ischemic Attack and Minor Stroke "DATAS II"

Active, not recruiting

Phase 2 Results N/A

Summary of Purpose

Rationale: To date, anticoagulant therapy in acute stroke has also been limited by excess hemorrhagic events. The oral anticoagulant dabigatran is a novel agent, which has been shown to be associated with much lower intracranial hemorrhage rates. It has been suggested that this agent may provide the superior benefits of anticoagulation in acute stroke, without the concomitant increase in hemorrhage risk...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 4 April 2018.

1 Jan 2015 17 Nov 2014 1 Jun 2018 1 Jun 2018 1 Apr 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Parallel Assignment


Not available